Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01007097 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 426
- Enrollment target
NCT01007097: Completed Phase 2 study, sponsored by Takeda.
NCT01007097 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 426 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (220% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01007097, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 426 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of multiple doses of TAK-875, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
Interventions
- DRUG TAK-875
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT01007097 record still lists
NCT01007097 is an interventional study that assigns participants to a tested intervention. The registered 426 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (220% higher).
The record links to 0 conditions, and to 1 intervention - of which TAK-875 is the first listed.
NCT01007097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01007097 about?
NCT01007097 is a clinical study titled "Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to determine the safety and efficacy of multiple doses of TAK-875, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
What is the current status of trial NCT01007097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 426 participants. The study started on 2009-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01007097?
The interventions under investigation include: TAK-875 (DRUG).
Who is sponsoring clinical trial NCT01007097?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01007097's enrollment target sits among peer trials
426 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790784 · 426 participants · Phase 3
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia